Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T15:57:32.516Z.
Calculation as of: 2026-10-06T15:57:32.516Z.
Quote observation: 2026-10-06T15:54:25.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 352cae2fe5eed9f02885becd1bbca6bb54c51239af0254a5780fc03f1b1dafbc
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
OnKure Therapeutics, Inc.
Market Cap
$103.06M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$104.28M
Price/FCF Ratio
N/A
TTM Avg
17.97
3Y Avg
17.97
5Y Avg
17.97
Market Cap
$104.68M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$105.38M
Price/FCF Ratio
3.69
TTM Avg
4.64
3Y Avg
13.17
5Y Avg
35.61
Market Cap
$106.08M
Price/FCF Ratio
N/A
TTM Avg
23.61
3Y Avg
13.61
5Y Avg
10.78
Market Cap
$108.30M
Price/FCF Ratio
N/A
TTM Avg
8.08
3Y Avg
8.08
5Y Avg
8.08
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| OnKure Therapeutics, Inc. (OKUR) | $103.06M | N/A | N/A | N/A | N/A |
| The Joint Corp. (JYNT)vs › | $103.00M | 24.36 | 107.29 | 57.88 | 61.33 |
| Anixa Biosciences, Inc. (ANIX)vs › | $104.28M | N/A | 17.97 | 17.97 | 17.97 |
| Polaryx Therapeutics, Inc. Common Stock (PLYX)vs › | $104.68M | N/A | N/A | N/A | N/A |
| Definitive Healthcare Corp. (DH)vs › | $105.38M | 3.69 | 4.64 | 13.17 | 35.61 |
| Cumberland Pharmaceuticals Inc. (CPIX)vs › | $106.08M | N/A | 23.61 | 13.61 | 10.78 |
| PolyPid Ltd. (PYPD)vs › | $99.04M | N/A | N/A | N/A | N/A |
| Korro Bio, Inc. (KRRO)vs › | $98.04M | N/A | N/A | N/A | N/A |
| Black Diamond Therapeutics, Inc. (BDTX)vs › | $108.30M | N/A | 8.08 | 8.08 | 8.08 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP)vs › | $108.57M | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
